SOLID BIOSCIENCES INC stock forecast: up to 1.99 USD SLDB stock price prognosis

STOCK

Forecast for Fri 18 Mar 2022 price 2.45

SOLID BIOSCIENCES INC stock price forecast for further price development up to 55.19% (time horizon: 1 day) and price target of 1.99 USD. Short-term (time horizon: 2 weeks) SOLID BIOSCIENCES INC share price prediction for 2022-03-18 with daily closed price projections

Key Facts

Symbol SLDB 

ISIN US83422E1055 

CUSIP 83422E105


Currency USD


Category Biological Products (No Diagnostic Substances)

Forecast price change %

Finance numbers

Revenue 3,335,000.0


Earnings per share -1.33


On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.

Summerized Form 10-K with GPT-2

Neither cytokine- nor coagulopathy-related abnormalities were observed. Expression for the fifth patient was 17.5% of normal control samples. In addition, the level of serum creatine kinase decreased from baseline. The six patients dosed in IGNITE DMD ranged in age from five to fourteen at baseline. Mission Our mission, which guides every aspect of our operations, is to cure Duchenne. Genes are prone to mutations, which can either be inherited or occur spontaneously. At 2E14 vg/kg, the level of expression ranged from 30% to 70% of wild-type dystrophin. Systemic administration of SGT-001 was generally well tolerated in both species. We believe this event was attributed to procedural errors. In October 2017, the first milestone was achieved under this agreement. We have the first right to enforce such licensed patents at our expense. We recorded the upfront license fee as a research and development expense in 2016. The Company has made no payments to Ultragenyx during the year ended December 31, 2020. The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. Additional guidances are expected to be finalized by the FDA. 8226; Breakthrough therapy designation. Accelerated evaluation may be granted by the CHMP in exceptional cases. Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10, 2020. A ruling by the Court is expected sometime this year. In addition, our product candidates, if approved, may not achieve commercial success. In October 2020, the FDA lifted the clinical hold placed on IGNITE DMD. Designation as a breakthrough therapy is within the discretion of the FDA. We might not receive such designation for our other product candidates. We currently have no medical affairs team. A broad range of legislative measures also have been introduced at the federal level.

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1707502/000156459021013153/0001564590-21-013153.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 17.36/100
    • Not in ideal financial position.
    • Historical view, profit is not growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
PARAMETRIC PORTFOLIO ASSOCIATES LLC 2021-03-31 70077
EcoR1 Capital, LLC 2021-03-31 9202702
Matisse Capital 2021-03-31 17500
Engineers Gate Manager LP 2021-03-31 39200
Point72 Hong Kong Ltd 2021-03-31 2155

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Concord Street Trust 2021-05-31 50658 Long
Fidelity Salem Street Trust 2021-04-30 197856 Long
iShares U.S. ETF Trust 2021-04-30 353 Long
BlackRock Funds 2021-04-30 1699 Long
Fidelity Salem Street Trust 2021-04-30 1622 Long

Insider trading for SOLID BIOSCIENCES INC

CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1727410 Ziolkowski Jennifer Lynn 2021-01-28 SALE Accept Accept Accept Accept
1727571 Morris Carl Ashley 2021-03-12 SALE Accept Accept Accept Accept
1727460 Ganot Ilan 2021-02-12 SALE Accept Accept Accept Accept
1727649 Schneider Joel Solomon Zev 2021-03-12 SALE Accept Accept Accept Accept

SOLID BIOSCIENCES INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.


On-Balance Volume information for SOLID BIOSCIENCES INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.


Accumulation / Distribution (A/D) indicator information for SOLID BIOSCIENCES INC. The indicator identify divergences between price and volume flow.


Aroon Oscillator information for SOLID BIOSCIENCES INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.


Average Directional Index (ADX) information for SOLID BIOSCIENCES INC. The index can be used to identify the strengh of a trend.


Moving Average Convergence Divergence (MACD) for SOLID BIOSCIENCES INC. The indicator helps to predict trend direction and the momentum of the trend.


Stochastic Oscillator as momentum indicator for SOLID BIOSCIENCES INC. The indicator is useful for identifying overbought and oversold levels.


Relative Strength Index (RSI) for SOLID BIOSCIENCES INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].


52W High 52W Low Market Cap

Similar shares


SOLID BIOSCIENCES INC on Nasdaq

SOLID BIOSCIENCES INC on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2022-02-21 1.99 2022-01-22 10:16
2022-02-22 2.02 2022-01-22 10:16
2022-02-23 2.05 2022-01-22 10:16
2022-02-24 2.07 2022-01-22 10:16
2022-02-25 2.09 2022-01-22 10:16
2022-03-04 2.22 2022-01-22 10:16
2022-02-28 2.12 2022-01-22 10:16
2022-03-03 2.20 2022-01-22 10:16
2022-03-02 2.17 2022-01-22 10:16
2022-03-07 2.25 2022-01-22 10:16
2022-03-08 2.27 2022-01-22 10:16
2022-03-10 2.32 2022-01-22 10:16
2022-03-09 2.29 2022-01-22 10:16
2022-03-11 2.34 2022-01-22 10:16
2022-03-14 2.36 2022-01-22 10:16
2022-03-15 2.38 2022-01-22 10:16
2022-03-16 2.40 2022-01-22 10:16
2022-03-17 2.43 2022-01-22 10:16
2022-03-01 2.15 2022-01-22 10:16
2022-03-18 2.45 2022-01-22 10:16
2022-01-24 1.34 2022-01-22 10:16
2022-01-25 1.38 2022-01-22 10:16
2022-01-26 1.40 2022-01-22 10:16
2022-01-27 1.42 2022-01-22 10:16
2022-01-28 1.46 2022-01-22 10:16
2022-01-31 1.50 2022-01-22 10:16
2022-02-01 1.53 2022-01-22 10:16
2022-02-02 1.56 2022-01-22 10:16
2022-02-03 1.60 2022-01-22 10:16
2022-02-04 1.65 2022-01-22 10:16
2022-02-07 1.67 2022-01-22 10:16
2022-02-08 1.69 2022-01-22 10:16
2022-02-09 1.73 2022-01-22 10:16
2022-02-10 1.77 2022-01-22 10:16
2022-02-11 1.80 2022-01-22 10:16
2022-02-14 1.83 2022-01-22 10:16
2022-02-15 1.86 2022-01-22 10:16
2022-02-16 1.90 2022-01-22 10:16
2022-02-17 1.94 2022-01-22 10:16
2022-02-18 1.96 2022-01-22 10:16